Goodwin Procter advised Bicara Therapeutics on the offering, and Ropes & Gray advised the underwriters.Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company, announced the pricing…
Bicara Therapeutics’ $315 Million IPO

Goodwin Procter advised Bicara Therapeutics on the offering, and Ropes & Gray advised the underwriters.Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company, announced the pricing…
You must be a Standard 1 Year member to access this content.
…
You must be a Standard 1 Year member to access this content.